Searchable abstracts of presentations at key conferences in endocrinology

ea0034p122 | Clinical practice/governance and case reports | SFEBES2014

Mitotane ameliorates testostoxicosis due to metastatic Leydig cell tumour

Johal Nicholas , Cullen Michael , Guest Peter , Porfiri Emilio , Arlt Wiebke

Leydig cell tumour (LCT) is a stromal testicular tumour comprising 3% of testicular neoplasms. Metastases are rare, have a poor prognosis and can appear many years after tumour removal. Current therapy for metastatic disease is limited, with no role for radiotherapy and poor efficacy of chemotherapy regimens. About 50–70% of metastatic LCT show associated steroid excess, comprising not only androgens but sometimes steroids physiologically produced in the adrenals. Here we...

ea0021p392 | Thyroid | SFEBES2009

An audit of the management of all patients with thyroid cancer treated with 131I for remnant ablation or persistent disease at a tertiary referral hospital between 2003 and 2008

Pazderska Agnieszka , Cullen Michael , O'Reilly Geraldine , Healy Marie Louise

Thyroid cancer is the most common endocrine malignancy. However, some aspects of its management remain controversial. The protocols provided by the British, European and American Thyroid Associations have changed recently and continue to evolve.We have audited the management of patients with thyroid cancer in a tertiary referral hospital and compared it with the guidelines from the Consensus Statement published by the European Thyroid Cancer Taskforce in...

ea0037ep1145 | Endocrine tumours | ECE2015

Mitotane treatment for metastatic Leydig cell tumour

Chortis Vasileios , Johal Nicholas , Cullen Michael , Bancos Irina , Guest Peter , Porfiri Emilio , Arlt Wiebke

Introduction: Testicular leydig cell tumours (LCTs) are rare stromal tumors often associated with androgen excess. Metastatic malignant LCTs typically show resistance to radiotherapy and cytotoxic chemotherapy, calling for alternative management options. Here we describe our experience with treatment of two patients with metastatic LCTs with the adrenolytic drug Mitotane.Patients/methods: Case 1: A 51-year-old patient presented with a 6 month hi...

ea0021p391 | Thyroid | SFEBES2009

Practical value of 131I whole body scan in follow up of patients with differentiated thyroid cancer

Pazderska Agnieszka , Cullen Michael , O'Reilly Geraldine , Crowley Vivion , Healy Marie Louise

Historically, the 131I whole body scan played a central role in the assessment of disease status in patients with differentiated thyroid cancer.In 2006, the European Thyroid Cancer Taskforce published a new Consensus Statement. It favoured the use of stimulated serum thyroglobulin measurement and neck ultrasound for follow up of disease activity. The use of diagnostic 131I whole body scan was no longer recommended as a routine test....